The Evolution of Influenza Immunisation

Traditional seasonal influenza vaccines rely on growing viral strains in chicken eggs or mammalian cells—a slow process that requires strain selection months in advance, often leading to mismatched strains and variable efficacy (typically 40% to 60%). Furthermore, these traditional vaccines target the rapidly mutating head of the viral hemagglutinin (HA) protein, necessitating annual reformulation.

To break this cycle, the biotechnology sector is leveraging mRNA platforms to develop next-generation and ultimately "universal" influenza vaccines. By utilizing mRNA to deliver genetic instructions that target highly conserved regions of the virus (such as the HA stalk or internal M2e domains), developers aim to produce vaccines that provide broad, multi-strain protection. The clinical progression of these candidates into Phase III registration trials represents a critical step toward establishing a new standard of care in infectious disease prevention.

Clinical Milestones and Regulatory Validation

The clinical viability of mRNA influenza vaccines has achieved major validation through several pivotal late-stage programmes:

• Moderna’s mRNA-1010 (mFlusiva): In May 2026, results from the pivotal Phase III "Fluent" trial (involving over 40,000 adults) demonstrated that mRNA-1010 achieved a 26.6% superior relative vaccine efficacy compared to standard-dose seasonal flu shots. Following this data, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously in June 2026 that the vaccine's benefits outweigh its risks for older adults, positioning it for potential launch ahead of the 2026–2027 season.

• Pfizer's Phase III Progress: Pfizer reported positive Phase III data showing 34.5% greater relative efficacy for its mRNA candidate against influenza A strains, although the programme is resolving non-inferiority parameters for B strains prior to final filing.

• GSK and Multivalent Combinations: GSK and other developers are actively evaluating multivalent and combination (flu/COVID-19) mRNA candidates in Phase II/III trials, aiming to simplify vaccination schedules and improve compliance.

The Regulatory and CMC Hurdles of Multivalent Platforms

While the clinical data is promising, navigating international registration programmes for mRNA vaccines is highly complex:

• Strain-Change Frameworks: Regulatory affairs teams must negotiate how annual strain updates will be managed. Securing approval for seasonal modifications without repeating large-scale Phase III efficacy trials is essential to maintaining the operational speed advantage of the mRNA platform.

• Multivalent LNP Formulation: Packaging multiple mRNA sequences (targeting different influenza A and B strains, or combining flu and SARS-CoV-2) into a single lipid nanoparticle (LNP) requires precise CMC (Chemistry, Manufacturing, and Controls) quality control to ensure uniform transduction and stability across international manufacturing sites.

• Correlates of Protection: Establishing immunologic correlates of protection (such as hemagglutination inhibition titers) as acceptable surrogates for clinical efficacy is a key regulatory negotiation topic for younger or lower-risk patient populations.

The Talent Mandate: Sourcing Global Regulatory Affairs Leaders

Steering these complex, multi-valent vaccine programmes through international registration requires VP of Regulatory Affairs and Global Regulatory Leads who possess specific vaccine development experience. General therapeutics regulatory leaders often lack familiarity with the specialised CBER (Center for Biologics Evaluation and Research) and VRBPAC advisory committee processes.

RSA prioritises several core competencies when placing regulatory leaders in the vaccine biotech sector:

• Vaccine BLA Submission Track Record: Direct experience leading Biologics License Applications (BLAs) for vaccines, managing submissions to FDA CBER, EMA, and securing WHO prequalification.

• Multivalent LNP Regulatory Navigation: A deep understanding of the CMC regulations governing multivalent lipid nanoparticle formulations and technology transfers across international manufacturing hubs.

• VRBPAC Advisory Preparation: Experience preparing briefing documents and orchestrating rehearsals for public FDA advisory committee presentations, defending clinical immunogenicity and safety data under intense public scrutiny.

As mRNA technology transitions from pandemic response to routine seasonal prevention, securing regulatory leaders who can negotiate flexible strain-update frameworks and manage global filings is the primary driver of commercial launch timelines and market leadership.